Know Labs, Inc. (KNW)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Know Labs, Inc. (KNW) trades at $2.14 with AI Score 47/100 (Grade C). Know Labs, Inc. is an American medical technology company focused on developing and commercializing its proprietary Bio-RFID technology. Market cap: $16.05M, Sector: Technology.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for KNW: KNW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates KNW against Technology peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
KNW: the 1 perspectives are evenly split.
How is this calculated? →Know Labs, Inc. (KNW) Technology Profile & Competitive Position
Know Labs, Inc. pioneers non-invasive medical diagnostics through its proprietary Bio-RFID technology, utilizing spectroscopy to identify molecular signatures. The company's primary focus is on developing a radiofrequency-based continuous glucose monitor, positioning it as an innovator in the rapidly evolving health technology sector.
What Is the Investment Thesis for KNW?
Know Labs, Inc. presents a compelling investment thesis centered on its proprietary Bio-RFID technology and its application in the high-demand non-invasive glucose monitoring market. The global prevalence of diabetes drives a continuous need for advanced, user-friendly monitoring solutions, a gap Know Labs aims to fill with its radiofrequency-based device. The company's Bio-RFID platform, leveraging spectroscopy for molecular identification, represents a potential paradigm shift in diagnostics, offering adaptability across various form factors. Key value drivers include the potential for significant market penetration upon successful regulatory approval, which would transition the company from its current pre-revenue status. However, investors must consider the inherent risks associated with a pre-revenue medical technology company, including the lengthy and stringent regulatory hurdles, the need for substantial capital for R&D and commercialization, and intense competition. The company's Beta of 1.76 indicates higher volatility, reflecting the speculative nature of early-stage biotech investments. Monitoring FDA progress and clinical trial results will be critical indicators of future potential.
Based on FMP financials and quantitative analysis
KNW Key Highlights
- Market Capitalization: $0.02 billion, reflecting its early-stage development and pre-revenue status.
- Beta: 1.76, indicating higher volatility relative to the broader market, typical for growth-oriented technology companies.
- Employee Base: Operates with a lean team of 12 employees, focused on specialized technology development and regulatory pathways.
- Proprietary Technology: Development centered on Bio-RFID, a spectroscopy-based platform designed for non-invasive molecular identification.
- Pre-Revenue Status: Currently focused on research, development, and navigating regulatory processes for its initial product, a non-invasive glucose monitor, rather than generating sales revenue.
Who Are KNW's Competitors?
KNW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MDA Macdonald Dettwiler & Associate | $42.11 | +3.34% | 6B | 66 |
| WATT Energous Corporation | $19.29 | -19.93% | $28.65M | 65 |
| SELX Selecta Biosciences, Inc. | $0.34 | +580.00% | $12.78M | 64 |
| APH Amphenol Corporation | $166.89 | +1.40% | $205.31B | 63 |
| NEON Neonode Inc. | $0.99 | +6.61% | $16.58M | 52 |
| HXGBF Hexagon AB (publ) | $8.63 | +2.38% | $22.21B | 52 |
| BCNAY Barco N.V. | $6.03 | -6.51% | $272.44M | 52 |
| HXGBY Hexagon AB (publ) | $8.50 | +1.31% | $22.82B | 52 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KNW's Key Strengths?
- Proprietary Bio-RFID technology offers a unique non-invasive approach to molecular identification.
- Initial focus on a high-demand market segment: non-invasive glucose monitoring for diabetes management.
- Adaptability of the core Bio-RFID technology for integration into various form factors and potential future applications.
- Potential for significant disruption in the medical device industry with a truly non-invasive diagnostic tool.
What Are KNW's Weaknesses?
- Currently a pre-revenue company, facing significant capital requirements for R&D and commercialization.
- High dependence on successful navigation of lengthy and stringent regulatory hurdles for product approval.
- Limited employee base of 12, which may constrain rapid development and scaling efforts.
- Lack of established market presence, brand recognition, and commercial infrastructure.
What Could Drive KNW Stock Higher?
- Successful completion of ongoing clinical trials for the non-invasive glucose monitor, demonstrating efficacy and safety.
- Submission of the Bio-RFID glucose monitoring device to the FDA for regulatory review and clearance.
- Receipt of FDA clearance or approval for its non-invasive glucose monitoring product, enabling commercial launch.
- Continued development and refinement of the Bio-RFID technology platform, potentially expanding its application scope.
What Are the Key Risks for KNW?
- Financial-distress signal — its Altman Z-Score of -4.31 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Significant regulatory hurdles and the potential for prolonged delays or outright failure to obtain FDA approval for its glucose monitoring product.
- Challenges in achieving commercial viability as a pre-revenue company, including market acceptance, scaling manufacturing, and establishing distribution channels.
- Intense competition from established medical device companies and other emerging non-invasive technologies in the diabetes management sector.
- Dependence on securing additional funding to support ongoing research, development, clinical trials, and eventual commercialization efforts.
- Risk of technological obsolescence or the emergence of superior alternative non-invasive glucose monitoring methods before market entry.
What Are the Growth Opportunities for KNW?
- Non-invasive Glucose Monitoring Market Expansion: The global market for continuous glucose monitoring is substantial and projected to grow significantly, driven by the increasing prevalence of diabetes worldwide. Know Labs' non-invasive approach, if successfully commercialized, could tap into a vast segment of this market, offering a less burdensome and more convenient solution than traditional finger-prick tests or current invasive CGMs. This market is estimated to reach tens of billions of dollars in the coming years, presenting a significant revenue opportunity as the company transitions from R&D to commercial operations.
- Bio-RFID Platform Diversification: The inherent adaptability of Know Labs' Bio-RFID technology allows for its integration into various form factors, including wearable devices, mobile applications, and stationary laboratory equipment. This versatility extends its potential beyond glucose monitoring to other diagnostic or material identification applications. Exploring and developing these additional applications, or licensing the technology to partners in diverse industries, could unlock new revenue streams and significantly expand the company's total addressable market over the long term, reducing reliance on a single product line.
- Regulatory Approval and Commercialization: Successful navigation of the stringent FDA regulatory process for its non-invasive glucose monitoring product is a critical growth catalyst. Achieving market clearance would enable the company to launch its device commercially, transitioning from a pre-revenue R&D entity to a revenue-generating enterprise. This milestone would not only validate the technology but also unlock significant investor confidence, facilitate market access, and allow the company to begin capturing market share within the next 1-3 years, depending on the regulatory timeline.
- Strategic Partnerships and Licensing: Given the broad applicability of the Bio-RFID technology, Know Labs could pursue strategic partnerships with larger medical device manufacturers, pharmaceutical companies, or technology firms. Such collaborations could accelerate product development, provide access to extensive distribution networks, and secure essential funding for ongoing research and commercialization efforts. Licensing agreements for the Bio-RFID platform in specific applications or geographic regions could generate recurring royalty revenues, providing a stable financial foundation and expanding the technology's reach over a 3-5 year horizon.
- International Market Entry: While currently focused on the US market, successful commercialization of its glucose monitor could pave the way for international expansion. The global diabetes epidemic ensures a worldwide demand for effective and convenient monitoring solutions. Pursuing regulatory approvals in key international markets, such as Europe, Asia, and other regions, would significantly broaden Know Labs' customer base and revenue potential, extending its growth trajectory beyond domestic borders and capitalizing on global health needs.
What Opportunities Does KNW Have?
- Growing global demand for non-invasive and continuous glucose monitoring solutions driven by increasing diabetes prevalence.
- Potential to diversify Bio-RFID applications beyond glucose monitoring into other diagnostic or industrial sectors.
- Strategic partnerships with larger medical device companies or technology firms to accelerate market entry and funding.
- Opportunity to capture significant market share by offering a superior, less burdensome alternative to existing monitoring methods.
What Threats Does KNW Face?
- Intense competition from established medical device manufacturers and other emerging non-invasive technology developers.
- Risk of delays or outright failure in obtaining necessary regulatory approvals, particularly from the FDA.
- Technological obsolescence or the emergence of superior alternative non-invasive glucose monitoring methods.
- Challenges in securing sufficient funding to sustain operations, complete development, and successfully commercialize products.
What Are KNW's Competitive Advantages?
- Proprietary Bio-RFID technology, which offers a unique spectroscopy-based approach to molecular identification and non-invasive sensing.
- Potential first-mover advantage in developing a radiofrequency-based continuous glucose monitor, differentiating it from existing invasive solutions.
- Strong intellectual property protection around its core technology and specific applications, creating barriers to entry for competitors.
- The adaptability of its Bio-RFID platform across multiple form factors and potential diagnostic applications, enabling diversified value creation.
What Does KNW Do?
Know Labs, Inc., an American enterprise headquartered in Seattle, Washington, is dedicated to the creation and market introduction of its proprietary technologies, primarily centered around its Bio-RFID platform. Established in 1998, the company initially operated under the name Visualant, Incorporated, before officially adopting its current name, Know Labs, Inc., in May 2018. At the heart of its operations is the Bio-RFID technology, an advanced system that employs spectroscopy to transmit electromagnetic energy through various substances or materials. This process enables the technology to precisely identify and capture their unique molecular signatures, offering a novel approach to biological and material analysis. The Bio-RFID system is designed with remarkable adaptability, allowing for its seamless incorporation into diverse form factors. These include compact wearable devices for personal use, mobile applications for on-the-go data access, and more robust stationary laboratory equipment for clinical or research settings. Know Labs, Inc.'s initial and most prominent commercial offering leveraging the Bio-RFID technology is a glucose monitoring product. This device is specifically engineered to furnish users with instantaneous data regarding their blood glucose concentrations, aiming to provide a non-invasive alternative to traditional glucose monitoring methods. The company's strategic focus is on addressing the significant global demand for more convenient and less intrusive solutions in diabetes management, positioning itself at the forefront of medical technology innovation.
What Products and Services Does KNW Offer?
- Develops and commercializes proprietary Bio-RFID technology.
- Bio-RFID uses spectroscopy to transmit electromagnetic energy through substances.
- Identifies and captures unique molecular signatures of materials.
- Initial commercial offering is a non-invasive glucose monitoring product.
- Provides instantaneous data regarding blood glucose concentrations.
- Bio-RFID technology is adaptable for integration into wearables, mobile apps, and lab equipment.
- Aims to innovate in the medical technology sector, particularly diabetes management.
How Does KNW Make Money?
- Currently pre-revenue, focused on research, development, and regulatory approval for its core technology.
- Intends to generate revenue through the sale of its non-invasive glucose monitoring devices upon commercialization.
- Potential future revenue streams from licensing its Bio-RFID technology for diverse applications in other industries.
- May explore recurring revenue models through associated mobile applications, data services, or subscription-based offerings for its devices.
What Industry Does KNW Operate In?
Know Labs, Inc. operates within the dynamic and rapidly evolving medical technology sector, specifically targeting the hardware, equipment, and parts industry with its innovative diagnostic solutions. The company is positioned within the broader diabetes management market, which is experiencing significant growth due to the increasing global prevalence of diabetes and a rising demand for more convenient and less invasive monitoring methods. Current market trends indicate a strong shift towards continuous glucose monitoring (CGM) devices and a growing interest in non-invasive technologies that can reduce patient burden. Know Labs aims to disrupt this landscape with its Bio-RFID technology, offering a radiofrequency-based approach that could differentiate it from existing invasive and minimally invasive solutions. The competitive landscape includes established medical device giants and numerous startups vying for market share in diabetes care, making regulatory approval and market acceptance critical for Know Labs' success in carving out its niche.
Who Are KNW's Key Customers?
- Individuals with diabetes seeking a non-invasive and convenient method for blood glucose monitoring.
- Healthcare providers and clinics looking for advanced diagnostic tools for diabetes management.
- Consumers interested in personal health and wellness monitoring technologies.
- Potentially other industries requiring precise molecular identification capabilities through Bio-RFID in the future.
Company Profile
Know Labs, Inc. operates in the Hardware, Equipment & Parts industry within the Technology sector. It is headquartered in Seattle, US. The company is led by CEO Ronald P. Erickson. KNW has traded publicly since 2006.
How Know Labs, Inc. Is Valued
Know Labs, Inc. carries a market capitalization of $16.05M, placing it in the micro-cap category. Relative to its peer group, KNW's quantitative score of 47/100 is below the peer average of 62/100.
Key Financial Metrics
Return on assets is -92.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -11.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.32 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -45.9%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Know Labs, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.31 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Know Labs, Inc. revenue of about $6.0M for fiscal 2026, with EPS near $-10.80.
KNW Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that key stakeholders believe in its growth potential.
- Community sentiment has shifted positively, with discussions highlighting innovative developments in their technology that could disrupt the market.
- The company has been gaining attention for its unique approach to non-invasive glucose monitoring, which resonates with growing health-conscious consumer trends.
- Recent partnerships and collaborations have been announced, which may enhance their market reach and credibility in the health tech space.
Bear Case
- Despite positive sentiment, some analysts express concerns about the scalability of their technology, questioning whether it can meet market demands effectively.
- Social media sentiment reflects skepticism regarding the company's ability to compete against established players in the health technology sector.
- Insider selling activity in the past raises red flags about potential underlying issues or lack of confidence among some executives.
- Market perception is mixed, as recent news cycles have highlighted challenges in regulatory approvals that could delay product launches.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
KNW Latest News
No recent news available for KNW.
KNW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KNW.
Price Targets
Wall Street price target analysis for KNW.
KNW MoonshotScore
What does this score mean?
The MoonshotScore rates KNW's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Classification
Industry Hardware, Equipment & PartsLeadership: Ronald P. Erickson
CEO
Ronald P. Erickson serves as the Chief Executive Officer of Know Labs, Inc., leading the company's strategic direction and operational execution. While specific details regarding his educational background, prior executive roles, or comprehensive career history before joining Know Labs are not publicly available in the provided sources, his leadership is instrumental in guiding the company's development of its proprietary Bio-RFID technology. As CEO of a pre-revenue medical technology firm, Mr. Erickson is responsible for overseeing research and development, managing a lean team of 12 employees, and navigating the complex pathways toward regulatory approval and commercialization.
Track Record: Under Ronald P. Erickson's leadership, Know Labs, Inc. has focused on the development and refinement of its proprietary Bio-RFID technology, particularly its application in non-invasive glucose monitoring. Key strategic decisions include the continued advancement of the technology platform and the dedicated pursuit of regulatory pathways for its initial commercial offering. His tenure has been marked by the company's commitment to innovation in the medical technology space, aiming to bring a novel non-invasive diagnostic solution to market.
Common Questions About KNW (Technology)
What does Know Labs, Inc. do?
Know Labs, Inc. is an American medical technology company that develops and commercializes its proprietary Bio-RFID technology. This innovative platform utilizes spectroscopy to transmit electromagnetic energy through substances, identifying and capturing their unique molecular signatures. The company's primary commercial focus is on a non-invasive glucose monitoring product, designed to provide instantaneous blood glucose data without the need for traditional finger-prick tests. The Bio-RFID system is highly adaptable, allowing for its integration into various form factors such as wearable devices, mobile applications, and stationary laboratory equipment, positioning Know Labs as a potential disruptor in health diagnostics.
How does Know Labs, Inc.'s Bio-RFID technology differentiate itself in the medical device market?
Know Labs, Inc.'s Bio-RFID technology differentiates itself through its unique non-invasive approach to molecular identification, particularly its application in glucose monitoring. Unlike traditional methods that require blood samples, Bio-RFID employs spectroscopy and electromagnetic energy to identify molecular signatures through the skin, aiming to provide real-time data without physical intrusion. This non-invasive characteristic offers significant advantages in user convenience and comfort, potentially increasing adherence to monitoring regimens. Furthermore, the technology's adaptability to various form factors—from wearables to mobile apps—and its potential for broader diagnostic applications beyond glucose monitoring, provide a versatile platform with a distinct competitive edge in the evolving medical device landscape.
What are the primary regulatory challenges Know Labs, Inc. faces for its glucose monitoring product?
Know Labs, Inc. faces significant regulatory challenges, primarily centered on obtaining approval from the U.S. Food and Drug Administration (FDA) for its non-invasive glucose monitoring product. The FDA's medical device approval process is stringent, requiring extensive clinical trials to demonstrate both the safety and efficacy of the device. This involves rigorous data collection, statistical analysis, and validation against established glucose monitoring standards. The company must prove that its Bio-RFID technology provides accurate and reliable glucose readings comparable to, or better than, existing approved methods. Navigating these complex regulatory pathways demands substantial financial investment, scientific expertise, and can be a lengthy, uncertain process, representing a critical hurdle for commercialization.
What are the key factors to evaluate for KNW?
Know Labs, Inc. (KNW) holds an AI score of 47/100 (low). Not financial advice.
How frequently does KNW data refresh on this page?
KNW prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven KNW's recent stock price performance?
Know Labs, Inc. (KNW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Bio-RFID technology offers a unique non-invasive approach to molecular identification. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider KNW overvalued or undervalued right now?
Valuing Know Labs, Inc. (KNW) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying KNW?
Before investing in Know Labs, Inc. (KNW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available beyond market cap and beta.
- Company is pre-revenue, making traditional financial analysis challenging.
- Reliance on provided 'AI Insight' for some risk and strength assessments.